Showing results (61-70 of 72) with videos related to
Sort By:
Pageof 8
European Journal of Medicinal Chemistry|February 20, 2026
Proline, a privileged fragment in drug design: advances and future perspectivesTing-Ting Li, Li-Rong Liu, Gong-Hui Ge, et al.Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy|October 29, 2022
(E)-2-styrylanthracene-9,10-dione derivatives as novel fluorescent probes: synthesis, photophysical properties and application in mitochondria imagingZhao-Ran Wang, Ting-Jian Zhang, Qiu-Yin Wang, et al.European Journal of Medicinal Chemistry|December 16, 2023
Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistanceWen-Han Xue, Kai-Li Liu, Ting-Jian Zhang, et al.Journal of Advanced Research|November 2, 2020
Development of a novel thymidylate synthase (TS) inhibitor capable of up-regulating P53 expression and inhibiting angiogenesis in NSCLCXin-Yang Li, De-Pu Wang, Guo-Qing Lu, et al.European Journal of Medicinal Chemistry|November 15, 2020
2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agentsYi Zhang, Ting-Jian Zhang, Xin-Yang Li, et al.Bioorganic Chemistry|December 16, 2021
Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER-2 dual-target inhibitors against cancer growth and angiogenesisXin-Yang Li, De-Pu Wang, Shuai Li, et al.Bioorganic Chemistry|December 12, 2025
Discovery of novel 2-azabicyclo[3.2.1]octane derivatives against non-small cell lung cancer from aconitine simplificationShuai Guo, Ting-Ting Li, Gong-Hui Ge, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 2, 2024
DHPS-Mediated Hypusination Regulates METTL3 Self-m6A-Methylation Modification to Promote Melanoma Proliferation and the Development of Novel InhibitorsJing-Si Guo, Jian Ma, Xi-He Zhao, et al.Bioorganic & Medicinal Chemistry|March 24, 2026
Exploring the potential of heterocyclic-containing tail approach in the development of novel covalent inhibitors dual-targeting EGFR and HER-2: design, synthesis and biological evaluationShuang Hao, Jing-Han Yan, Rui Wang, et al.Bioorganic & Medicinal Chemistry Letters|August 5, 2025
Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancerGong-Hui Ge, Shuai Guo, Ting-Ting Li, et al.Pageof 8